贝那普利治疗糖尿病性肾病对血浆NO及ET-1的影响研究
Research on effect of benazepril treat with diabetic nephropathy on Plasma NO and ET-1
李俊岩 1司芹芹 1牛晓红1
作者信息
- 1. 山西省长治医学院附属和济医院 内分泌科,山西 长治 046000
- 折叠
摘要
目的 探讨贝那普利治疗糖尿病性肾病(DN)的临床疗效及对血浆NO、ET-1水平的影响.方法 使用随机数字表法将100例DN患者分为2组(50例),A组实施基础治疗,B组加用贝那普利,另选取50例单纯糖尿病患者作为对照组,观察3组的血浆NO(一氧化氮)、ET-1(内皮素-1)水平变化,比较临床疗效.结果 A、B2组治疗前后的NO、ET-1、AngⅡ水平显著低于对照组(P<0.05);B组治疗后的NO水平明显高于A组,ET-1、AngⅡ水平明显低于A组(P<0.05).B组患者的治疗总有效率为86.00％,显著高于对照组的58.00％(P<0.05).结论 在DN的临床治疗中应用贝那普利能够有效调节血浆NO、ET-1水平,发挥肾脏保护作用,提高治疗效果.
Abstract
Objective To evaluate the clinical efficacy and effect of benazepril treat with diabetic nephropathy on Plasma NO and ET-1. Methods 100 cases of DN patients were divided into two groups by random number table (50cases), group A with basic treatment, group B increased benazepril. Selected another 50 cases of simple diabetic patients as control group, observed the plasma NO (nitric oxide) and ET-1 (ET-1) levels changes of three groups,and compared the clinical efficacy. Results The levels of NO, ET-1 and Ang II in A group and B group were significantly lower than those in control group (P<0.05); the level of NO in B group was higher than that in group A, and the level of ET-1 and Ang II was lower than that of group A(P<0.05). The total effective rate of B group was 86.00％, which was significantly higher than that of control group 58.00％(P<0.05). Conclusion The clinical application benazepril treat with DN can effectively regulated plasma NO and ET-1 levels, protect the kidneys, and improve the therapeutic effect.
关键词
糖尿病性肾病/贝那普利/NO/ET-1Key words
diabetic nephropathy/benazepril/NO/ET-1引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据